Actively Recruiting
Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and Unresectable Metastases: a Retrospective, Europe-wide, Pooled Cohort Study
Led by Insel Gruppe AG, University Hospital Bern · Updated on 2026-03-18
3200
Participants Needed
1
Research Sites
146 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating whether removing the main tumor improves long-term survival and reduces complications in patients with small intestinal neuroendocrine tumors (siNETs) that have spread and cannot be cured completely. Current guidelines recommend surgery only for patients with symptoms like intestinal blockage or bleeding, but it is unclear if surgery benefits patients without symptoms. This Europe-wide, retrospective study aims to provide clear evidence on this question by analyzing patient outcomes over 10 years. The study groups patients based on whether they had surgery to remove the primary tumor within six months of diagnosis or received systemic treatment alone. This comparison will help determine the impact of tumor removal in patients who do not show symptoms. The study involves histopathological reviews and collects data from multiple neuroendocrine tumor referral centers across Europe to guide future clinical practice. Participants' health outcomes will be tracked for 10 years, focusing on overall survival, disease progression, risks of intestinal blockage or blood flow problems, and surgical risks. Researchers will also evaluate factors that influence long-term survival. This comprehensive follow-up includes monitoring morbidity and mortality related to surgery, aiming to inform treatment guidelines and improve care for patients with metastatic siNETs.
CONDITIONS
Brief Title
Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and Unresectable Metastases: a Europe-wide Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with small intestinal neuroendocrine tumors (siNET) and non-curative metastatic disease between January 1, 2005, and December 31, 2021.
You will not qualify if you...
- Patients with siNET grade 3 tumors.
- Patients with resectable metastatic disease at initial diagnosis.
- Patients with non-resectable primary tumor at initial diagnosis.
- Patients showing symptoms such as small intestinal obstruction or bleeding at initial diagnosis.
- Patients with imaging suggesting likely obstruction (bowel dilatation, mesenteric fibrosis) at initial diagnosis.
- Patients who have documented rejection for further use of their data for scientific purposes.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) to confirm eligibility based on medical records
Duration - Retrospective data collection covering diagnoses from 2005 to 2021
Participants' tumor samples are reviewed to group them based on whether primary tumor resection was performed within 6 months after diagnosis.
Data review without additional visits
Duration - Up to 10 years
Participants' outcomes including survival, progression, and complications are observed over time based on collected medical data.
No direct visits; outcomes assessed through medical records and data collection
Trial Site Locations
Total: 1 location
1
UHI Berne
Bern, Switzerland, 3010
Actively Recruiting
Research Team
E
Eliane Dohner
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here